Progen Company Description

Progen Co., Ltd., a biotechnology company, engages in platform-based drug discovery and development activities.

The company’s NTIG platform technology is used for the development of anti-cancer and immune disease treatments.

It develops PG-102 for the treatment of obesity with T2DM to control blood sugar, improve metabolic function, and reduce weight in the gastrointestinal tract and adipocytes.

The company was founded in 1998 and is based in Seoul, South Korea.

Progen Co., Ltd.

Country	South Korea
Founded	1998
Industry	Biological Products, Except Diagnostic Substances

Contact Details

Address: 7th floor, Bio Innovation Park Seoul, 07630 South Korea
Phone	82 2 6098 2800
Website	progen.co.kr

Stock Details

Ticker Symbol	296160
Exchange	Korea New Exchange
Fiscal Year	January - December
Reporting Currency	KRW
SIC Code	2836